Table 1.
Year | Author | Study Design | Disease | Patients (n) | ONJ Cases | Prevalence (%) | Used Agent |
---|---|---|---|---|---|---|---|
2005 | Bamias [17] | pros | breast ca | 70 | 2 | 2.86 | Z, PZ, ZI |
pros | mult myel | 111 | 11 | 9.91 | Z, PZ, ZI | ||
pros | prostate ca | 46 | 3 | 6.52 | Z, PZ, ZI | ||
Durie [18] | web survey | mult myel | 904 | 62 | 6.86 | Z, P | |
web survey | breast ca | 299 | 13 | 4.35 | |||
Guarneri [19] | retro | breast ca | 48 | 3 | 6.25 | P | |
2006 | Badros [20] | retro | mult myel | 340 | 11 | 3.24 | P, Z, PZ |
Calvo-Villas [21] | retro | mult myel | 64 | 7 | 10.94 | Z | |
Dimopoulos [22] | pros | mult myel | 202 | 15 | 7.43 | Z | |
Sanna [23] | pros | breast ca | 81 | 5 | 6.17 | P, Z | |
Tosi [24] | retro | mult myel | 259 | 9 | 3.47 | Z | |
Zervas [25] | pros | mult myel | 254 | 28 | 11.02 | Z, P, ZP | |
Ortega [26] | ? | breast ca | 126 | 2 | 1.59 | Z | |
2007 | Aguiar Bujanda [27] | css | breast ca | 35 | 4 | 11.43 | Z |
Corso [28] | retro | mult myel | 106 | 8 | 7.55 | Z, PZ | |
García Sáenz [29] | pros | prostate ca | 104 | 3 | 2.88 | Z | |
Jadu [30] | retro | mult myel | 655 | 21 | 3.21 | P | |
Ortega [31] | retro | prostate ca | 52 | 6 | 11.54 | Z | |
Petrucci [32] | ? | mult myel | 311 | 22 | 7.07 | Z, P, PZ | |
Wang [33] | retro | mult myel | 292 | 11 | 3.77 | Z, P, Z | |
retro | breast ca | 81 | 2 | 2.47 | Z, P, Z | ||
retro | prostate ca | 69 | 2 | 2.9 | Z, P, Z | ||
Lipton [34] | prosp | breast ca | 211 | 0 | 0 | D | |
Pozzi [35] | retro | mult myel | 1402 | 28 | 2 | Z, PZ | |
2008 | Boonyapakorn [36] | pros | mult myel | 58 | 10 | 17.24 | P, PZ, IZ, Z |
Fehm [37] | retro | breast ca | 233 | 10 | 4.29 | Z, ICPZ | |
Ibrahim [38] | retro | breast ca | 220 | 5 | 2.27 | PZ, Z | |
retro | mult myel | 59 | 2 | 3.39 | PZ, Z | ||
Walter [39] | css | prostate ca | 43 | 8 | 18.6 | IZ, PZ, Z | |
Yonemori [40] | prosp | breast ca | 18 | 0 | 0 | D | |
Ellis [41] | prosp | breast ca | 106 | 0 | 0 | D | |
Christodoulou [42] | retro | breast ca | 75 | 2 | 2.67 | Z, I | |
retro | prostate ca | 11 | 1 | 9.1 | Z, I | ||
Estilo [43] | retro | breast ca | 134 | 18 | 13.43 | P, Z, PZ | |
retro | prostate ca | 31 | 4 | 12.9 | P, Z, PZ | ||
retro | mult myel | 145 | 6 | 4.14 | P, Z, PZ | ||
Hoff [14] | retro | breast ca | 1338 | 16 | 1.2 | P, Z | |
retro | mult myel | 548 | 13 | 2..37 | P, Z | ||
Montefusco [44] | retro | mult myel | 178 | 9 | 5.06 | BP | |
Musto [45] | prosp | mult myel | 81 | 1 | 1.23 | Z | |
2009 | Walter [46] | css | breast ca | 75 | 4 | 5.33 | Z, PZI |
Aragon-Ching [47] | pros | prostate ca | 60 | 11 | 18.33 | Z | |
Cetiner [48] | pros | mult myel | 32 | 5 | 15.63 | Z | |
Crawford [49] | retro | breast ca | 113 | 10 | 3.5 | P, PZ, Z | |
Dimopoulos [50] | pros | mult myel | 128 | 16 | 12.5 | Z | |
Haidar [51] | retro | prostate ca | 51 | 2 | 3.92 | Z | |
Ripamonti [52] | retro | breast ca | 590 | 18 | 3.05 | P, PZ, Z | |
prosp | breast ca | 112 | 2 | 1.79 | P, PZ, Z | ||
Vahtsevanos [53] | retro | breast ca | 1041 | 32 | 3.07 | Z, P, I, PZ, IZ | |
retro | mult myel | 539 | 46 | 8.53 | P, PZ, Z | ||
retro | prostate ca | 41 | 2 | 4.88 | P, Z, ZI | ||
Fizazi [54] | prosp | prostate | 17 | 0 | 0 | P, Z | |
prosp | breast ca | 16 | 0 | 0 | P, Z | ||
prosp | prostate ca | 33 | 0 | 0 | D | ||
prosp | breast ca | 30 | 0 | 0 | D | ||
Bonomi [55] | retro | breast ca | 238 | 7 | 2.94 | P, PZ, Z | |
retro | protate ca | 46 | 1 | 2.17 | P, PZ, Z | ||
Stumpe [56] | retro | mult myel | 128 | 3 | 2.34 | P, Z, PZ | |
retro | breast ca | 241 | 1 | 0.41 | P, Z, PZ | ||
retro | prostate ca | 128 | 1 | 0.78 | P, Z, PZ | ||
2010 | Walter [16] | retro | mult myel | 81 | 4 | 4.94 | U, PZ |
css | mult myel | 78 | 16 | 20.51 | Z, PZ, IZ, PZI | ||
Bantis [11] | retro | prostate ca | 60 | 9 | 15 | Z | |
Gimsing [57] | retro | breast ca | 250 | 8 | 3.2 | P normal dose (90 mg) | |
retro | breast ca | 252 | 2 | 0.79 | P low dose (30 mg) | ||
Pakovic [58] | retro | mult myel | 190 | 2 | 1.05 | P, PI, I | |
Stopeck [59] | prosp | breast ca | 1020 | 20 | 1.96 | D | |
prosp | breast ca | 1013 | 14 | 1.38 | Z | ||
2011 | Fizazi [60] | prosp | prostate ca | 950 | 22 | 2.32 | D |
prosp | prostate ca | 951 | 12 | 1.26 | Z | ||
Quispe [61] | retro | breast ca | 110 | 10 | 9.09 | Z | |
2012 | Ding [62] | retro | breast ca | 181 | 1 | 0.55 | P, I, Z |
Miyazaki [63] | retro | prostate ca | 111 | 9 | 8.11 | Z | |
Smith [64] | prosp | prostate ca | 716 | 33 | 4.61 | D | |
Thumbigere-Math [65] | retro | breast ca | 190 | 8 | 4.21 | P, PZ, Z | |
retro | mult myel | 83 | 6 | 7.23 | P, PZ, Z | ||
retro | prostate ca | 84 | 2 | 2.38 | P, PZ, Z | ||
Rugani [66] | retro | breast ca | 48 | 5 | 10.42 | Z | |
Then [67] | retro | mult myel | 120 | 23 | 19.17 | P, Z, I | |
Martin [68] | prosp | breast ca | 1026 | 0 | 0 | D | |
Henry [69] + Saad [70] | prosp | mult myel | 180 | 6 | 3.33 | D,Z | |
2013 | Assaf [71] | retro | breast ca | 95 | 9 | 9.47 | P, I, Z, ZI, PI |
retro | mult myel | 42 | 5 | 11.9 | P, I, Z, ZI, PI | ||
Coleman [72] | prosp | breast ca | 1065 | 5 | 0.47 | Z | |
Brufsky [73] | retro | breast ca | 159 | 6 | 3.77 | P, Z, PZ | |
retro | breast ca | 62 | 1 | 1.61 | P, Z, PZ | ||
Rathbone [74] | prosp | breast ca | 1681 | 26 | 1.55 | Z | |
2014 | Barrett-Lee [75] | prosp | breast ca | 697 | 9 | 1.29 | Z |
Coleman [76] | prosp | breast ca | 1685 | 26 | 1.54 | Z | |
Jackson [77] | prosp | mult myel | 981 | 36 | 3.67 | Z | |
Gnant [78] | prosp | breast ca | 900 | 0 | 0 | Z | |
2015 | Vidal-Real [79] | retro | prostate ca | 43 | 9 | 20.93 | Z |
retro | breast ca | 15 | 4 | 26.67 | Z | ||
retro | mult myel | 18 | 0 | 0 | Z | ||
Rodrigues [80] | prosp | prostate ca | 324 | 2 | 0.62 | Z | |
2016 | Stopeck [81] | prosp | breast ca | 318 | 20 | 6.29 | D |
prosp | breast ca | 334 | 18 | 5.39 | ZD | ||
prosp | prostate ca | 147 | 12 | 8.16 | D | ||
prosp | prostate ca | 118 | 7 | 5.93 | ZD |
Abbreviations: prosp (prospective), retro (retrospective), ccs (cross-sectional study), ? (unknown), ca (cancer), mult myel (multiple myeloma), Z (zoldronate), P (pamidonate), I (ibandronate), D (denosumab).